AU2010303142B2 - Bispecific death receptor agonistic antibodies - Google Patents

Bispecific death receptor agonistic antibodies Download PDF

Info

Publication number
AU2010303142B2
AU2010303142B2 AU2010303142A AU2010303142A AU2010303142B2 AU 2010303142 B2 AU2010303142 B2 AU 2010303142B2 AU 2010303142 A AU2010303142 A AU 2010303142A AU 2010303142 A AU2010303142 A AU 2010303142A AU 2010303142 B2 AU2010303142 B2 AU 2010303142B2
Authority
AU
Australia
Prior art keywords
antibody
bispecific
cells
apoptosis
apomab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010303142A
Other languages
English (en)
Other versions
AU2010303142A1 (en
Inventor
Peter Bruenker
Claudia Ferrara Koller
Sandra Grau
Sylvia Herter
Christoph Lampert
Ekkehard Moessner
Pablo Umana
Inja Waldhauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Glycart AG
Original Assignee
Roche Glycart AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart AG filed Critical Roche Glycart AG
Publication of AU2010303142A1 publication Critical patent/AU2010303142A1/en
Priority to AU2013203431A priority Critical patent/AU2013203431A1/en
Application granted granted Critical
Publication of AU2010303142B2 publication Critical patent/AU2010303142B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2010303142A 2009-09-29 2010-09-27 Bispecific death receptor agonistic antibodies Ceased AU2010303142B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203431A AU2013203431A1 (en) 2009-09-29 2013-04-10 Bispecific death receptor agonistic antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09171659.7 2009-09-29
EP09171659 2009-09-29
PCT/EP2010/064209 WO2011039126A1 (en) 2009-09-29 2010-09-27 Bispecific death receptor agonistic antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203431A Division AU2013203431A1 (en) 2009-09-29 2013-04-10 Bispecific death receptor agonistic antibodies

Publications (2)

Publication Number Publication Date
AU2010303142A1 AU2010303142A1 (en) 2012-03-15
AU2010303142B2 true AU2010303142B2 (en) 2013-05-09

Family

ID=43086853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010303142A Ceased AU2010303142B2 (en) 2009-09-29 2010-09-27 Bispecific death receptor agonistic antibodies

Country Status (18)

Country Link
US (1) US9481730B2 (https=)
EP (1) EP2483310B1 (https=)
JP (1) JP5695059B2 (https=)
KR (1) KR101508043B1 (https=)
CN (1) CN102574921B (https=)
AU (1) AU2010303142B2 (https=)
BR (1) BR112012006326A2 (https=)
CA (1) CA2773515C (https=)
CY (1) CY1115639T1 (https=)
DK (1) DK2483310T3 (https=)
ES (1) ES2505269T3 (https=)
HR (1) HRP20141032T1 (https=)
IL (1) IL218437A (https=)
MX (1) MX2012003598A (https=)
PL (1) PL2483310T3 (https=)
PT (1) PT2483310E (https=)
SI (1) SI2483310T1 (https=)
WO (1) WO2011039126A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2756244A1 (en) * 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
PE20141017A1 (es) * 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
US20140242083A1 (en) * 2013-02-26 2014-08-28 Roche Glycart Ag Anti-mcsp antibodies
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
AU2015244814B2 (en) * 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
JP6810687B2 (ja) * 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
US11091547B2 (en) 2014-11-12 2021-08-17 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2016103205A1 (en) * 2014-12-23 2016-06-30 Universita' Degli Studi Di Parma Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
CN104818295A (zh) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 制备和筛选表达双特异性抗体细胞株的方法
EP3973980A1 (en) 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055395A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
EP3710482A4 (en) * 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
US12194000B2 (en) * 2018-08-01 2025-01-14 The Wistar Institute Of Anatomy And Biology Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
EP4615874A1 (en) 2022-11-10 2025-09-17 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
TW202509077A (zh) * 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體４結合之抗體
TW202528350A (zh) * 2023-11-10 2025-07-16 大陸商信達生物製藥（蘇州）有限公司 抗ｄｒ５和ｃｅａｃａｍ５的雙特異性抗體及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US5965710A (en) * 1993-08-21 1999-10-12 Imperial Cancer Research Technology Limited Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
WO2002008291A2 (de) * 2000-07-20 2002-01-31 Gundram Jung Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
WO2002085946A1 (en) * 2001-04-20 2002-10-31 Immunex Corporation Bispecific antibodies that bind trail-r1 and trail-r2
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074397A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US20070031414A1 (en) * 2005-02-02 2007-02-08 Adams Camellia W DR5 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US5965710A (en) * 1993-08-21 1999-10-12 Imperial Cancer Research Technology Limited Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
WO2002008291A2 (de) * 2000-07-20 2002-01-31 Gundram Jung Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
WO2002085946A1 (en) * 2001-04-20 2002-10-31 Immunex Corporation Bispecific antibodies that bind trail-r1 and trail-r2
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074397A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US20070031414A1 (en) * 2005-02-02 2007-02-08 Adams Camellia W DR5 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERRMANN, T., et al., "Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95," Cancer Research, 15 February 2008, Vol. 68, No. 4, pages 1221-1227. *

Also Published As

Publication number Publication date
PL2483310T3 (pl) 2015-01-30
JP2013505732A (ja) 2013-02-21
HRP20141032T1 (hr) 2015-01-30
ES2505269T3 (es) 2014-10-09
WO2011039126A1 (en) 2011-04-07
MX2012003598A (es) 2012-04-20
US20120184718A1 (en) 2012-07-19
EP2483310A1 (en) 2012-08-08
SI2483310T1 (sl) 2014-12-31
BR112012006326A2 (pt) 2016-11-16
US9481730B2 (en) 2016-11-01
DK2483310T3 (da) 2014-09-01
CA2773515A1 (en) 2011-04-07
AU2010303142A1 (en) 2012-03-15
CY1115639T1 (el) 2017-01-04
CN102574921B (zh) 2016-05-04
KR20120056857A (ko) 2012-06-04
IL218437A (en) 2017-04-30
EP2483310B1 (en) 2014-08-13
JP5695059B2 (ja) 2015-04-01
CN102574921A (zh) 2012-07-11
IL218437A0 (en) 2012-04-30
HK1169132A1 (zh) 2013-01-18
PT2483310E (pt) 2014-10-07
CA2773515C (en) 2015-04-28
KR101508043B1 (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
AU2010303142B2 (en) Bispecific death receptor agonistic antibodies
US12486336B2 (en) Binding molecules with modified J-chain
CN108350084B (zh) 新的间皮素抗体和包含其的组合物
JP2013505732A5 (https=)
US20180194862A1 (en) Bispecific binding proteins
KR20220071263A (ko) Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
US20170306044A1 (en) Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2017059387A1 (en) Binding molecules with modified j-chain
HK1217958A1 (zh) 四价双特异性抗体
JP2024504471A (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
US20230235090A1 (en) Bispecific antibody and use thereof
KR20250027562A (ko) Dll3 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
WO2023109888A1 (zh) 抗ang2-vegf双特异性抗体及其用途
TW202436358A (zh) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途
CN121666399A (zh) 针对EpCAM的多特异性抗原结合蛋白
CN112500491B (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
JP2024543134A (ja) 修飾されたタンパク質又はポリペプチド
EP4585618A1 (en) Anti-ilt4 antibody and pharmaceutical use thereof
AU2013203431A1 (en) Bispecific death receptor agonistic antibodies
HK1169132B (en) Bispecific death receptor agonistic antibodies
KR20260032990A (ko) Her2 키메라 항원 수용체 분비
HK40054516A (en) Novel mesothelin antibody and composition comprising the same
CN120530142A (zh) 多特异性多肽复合物
EA051272B1 (ru) Мультиспецифическое антитело, нацеленное на bcma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired